Comorbidities are significantly associated with the primary composite of SOLVD time to death or heart failure hospitalization ( SOLVD prevention : HR 4.8 , CI : 3.2-7 .18 , P < 0.0001 ; SOLVD treatment : HR 2.9 , CI : 2.12-3 .95 , P < 0.0001 for more than four comorbidities vs. no comorbidities ) , and to death , heart failure hospitalization , and cardiovascular death where the effect of the number of coexisting comorbidities was additive .